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Paracoccidioidomycosis (PCM) is an endemic systemic mycosis in Latin America, with
the highest prevalence in Brazil, Colombia, and Venezuela. Fungi of the Paracoccidioides
genus are etiologic agents of the disease. The 15 amino acid peptide P10 is derived
from gp43, the main diagnostic antigen of Paracoccidioides brasiliensis. We previously
reported that P10-pulsed dendritic cells (DCs) induce a protective response against
P. brasiliensis. Presently, dexamethasone-treated BALB/c mice were intratracheally
infected with P. brasiliensis Pb18 to establish the therapeutic efficacy of P10-pulsed
DCs. Immunosuppressed and infected animals that received DCs had a reduction
in their fungal burden, and this result was most pronounced in mice receiving
DCs primed with P10. The efficacy of therapeutic DCs was significantly augmented
by concomitant treatment with trimethoprim-sulfamethoxazole. Additionally, primed-
DCs with or without the antifungal drug induced a beneficial Th1-biased immune
response and significantly reduced tissue damage. In conclusion, these studies
with immunocompromised mice demonstrate that P10-pulsed DCs with or without
concomitant antifungal drugs are potently effective in combating invasive PCM. These
findings support further translational studies to validate the use of P10-primed DCs for
PCM in immunocompetent and immunosuppressed hosts.
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INTRODUCTION
Paracoccidioidomycosis (PCM), caused by thermally dimorphic fungi of the Paracoccidioides
genus, is one of the most important systemic granulomatous diseases in Latin America (Taborda
et al., 2015). PCM is particularly prevalent in Brazil, affecting mainly rural workers (Restrepo, 1985;
Travassos and Taborda, 2012b). In Brazil, approximately 1,853 (∼51.2%) of 3,583 confirmed deaths
due to systemic mycoses from 1996 to 2006 were caused by PCM (Prado et al., 2009). Phylogenetic
analyses have revealed that the clinically relevant Paracoccidioides species include Paracoccidioides
brasiliensis, comprised of the three cryptic species S1, PS2, and PS3 (Theodoro et al., 2012), and
Paracoccidioides lutzii (Teixeira et al., 2013).
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Acquisition of Paracoccidioides spp. follows the inhalation
of conidia, which are deposited into the lower respiratory
tract. These propagules subsequently undergo morphogenic
transformation into yeast forms, which constitute the pathogenic
morphology in tissues (Taborda et al., 2015). PCM has two
main clinical forms that are predicated upon the immunological
status of the infected host. Within weeks to months after initial
infection, young adults often develop the acute or subacute
forms of disease, and these are typically aggressive and require
immediate antifungal treatment (Bocca et al., 2013). The chronic
form of PCM is manifested months or years after infection, and
disease varies in severity, although this form can be as aggressive
as the acute form (Bocca et al., 2013).
Although polyene and azoles as well as the combination of
trimethoprim and sulfamethoxazole are the typical therapeutics
administered to patients with PCM, antifungal treatment is
prolonged, frequently over 2 years, and failures and/or relapses
occur (Travassos et al., 2008b; Bocca et al., 2013).
An experimental vaccine against P. brasiliensis has been
studied (Travassos and Taborda, 2012b) using a 15 mer
peptide, known as peptide 10 or P10, with the sequence:
QTLIAIHTLAIRYAN (Taborda et al., 1998). P10 is derived
from the major diagnostic antigen of PCM, the 43,000 Daltons
glycoprotein known as gp43 (Travassos et al., 1995). Over the
past 10 years, the properties and several different forms of
delivery of P10 have been studied, and have contributed to
validating this peptide as a potential candidate for a human
vaccine (Iwai et al., 2003; Travassos et al., 2008a; Travassos and
Taborda, 2012b; Taborda et al., 2015). Using dexamethasone-
treated mice, immunization with P10 has been shown to
efficiently modulate the immune response in immunosuppressed
hosts. Protection against pulmonary challenge with P. brasiliensis
has been demonstrated by increased animal survival, reduced
lung fungal burden and reduced pulmonary fibrosis in P10
immunized mice as compared to control animals (Muñoz et al.,
2014).
We previously demonstrated protective immunity against
murine Paracoccidioides brasiliensis infection after sub-cutaneous
or intravenous injection of P10-primed dendritic cells (DCs).
Mice receiving the P10-primed DCs had a mixed cytokine
response pattern with a predominance of Th1-type activation
and a significant reduction of fungal burdens in comparison
with control animals. This data supported our proposal that
P10-primed DCs are promising therapeutics in the setting of
established fungal infection (Magalhães et al., 2012; Thind et al.,
2015). DCs are powerful inducers of T-lymphocyte immune
responses against Paracoccidioides antigens (Magalhães et al.,
2012; Thind et al., 2015). The administration of in vitro
gp43-pulsed DCs into mice results in increased productions
of IL-2 and IFN-γ by CD4+ T cells isolated from regional
lymph nodes (Ferreira et al., 2003). There is significant
interest in adoptive transfer of DCs as a means to harness
T-cell mediated immunity as a therapy to combat pathogenic
fungi, which is demonstrated by studies with DCs pulsed
with fungal cells or with fungal RNA from Candida albicans,
Aspergillus fumigatus, Cryptococcus gattii, and Cryptococcus
neoformans (D’Ostiani et al., 2000; Bozza et al., 2003; Siegemund
and Alber, 2008; Roy and Klein, 2012; Ueno et al., 2015,
2016).
However, there is yet limited information as to whether
this modality of cell-induced therapy would be effective in the
setting of immunocompromised patients, which is important
since PCM is a frequent mycological cause of morbidity and
mortality in patients with HIV in Brazil (Prado et al., 2009). In
the present work, we simulated the acute/subacute form of PCM
in immunocompromised mice by administering dexamethasone,
which suppresses host immune responses through multiple
mechanisms, including modulating inflammatory cytokines
(Chung et al., 2011; Muñoz et al., 2014) prior to infection. Our
findings show that the administration of P10-primed DCs to
dexamethasone suppressed mice infected with P. brasiliensis are
therapeutic in the setting of compromised immunity.
MATERIALS AND METHODS
Animal Use and Ethics Statement
BALB/c mice (6-to 8-week-old, males) used for infection and
bone marrow harvesting were bred at the School of Medicine –
University of São Paulo in pathogen-free conditions. All animal
experiments were performed in strict accordance with the
Brazilian Federal Law 11,794 establishing the Animal Protection
Code for the State of São Paulo. This study was approved by
the Ethics Committee on Animal Experiments at the School of
Medicine, University of São Paulo (189/14).
Fungus and Inoculum Preparation
The virulent isolate P. brasiliensis Pb18 was cultivated on solid
Sabouraud medium at 37◦C for 7 days. The fungus was collected
and washed three times in phosphate buffered saline (PBS, pH
7.2). After decanting large and agglutinated cells, small isolated
yeast cells were counted in a Neubauer chamber. The yeast cells
used for experimentation displayed>95% viability as determined
by staining with Trypan blue.
Immunosuppressed Mice
The animals were immunosuppressed as previously described
(Muñoz et al., 2014). Dexamethasone phosphate (Sigma, St
Louis, MO, United States) was administrated daily in drinking
water and the dose was calculated as 0.15 mg/kg considering an
average water intake of 5 ml per day. Dexamethasone phosphate
treatment was initiated 20 days before intratracheal (i.t.) infection
and continued until the end of experiment. Immunosuppression
was confirmed by the blood leukocyte levels in comparison
with untreated mice. Animals were maintained in isolator cages.
Cages were exchanged twice a week in a laminar flow hood
and all bedding, food and water was autoclaved prior to use.
Total leukocyte counts were determined using ∼200 µl of
blood obtained via the ocular plexus. The blood was mixed
with 20 µL of ACD (citric acid, sodium citrate, dextrose) to
prevent clot formation and then Turk solution was used to
hemolyze erythrocytes and stain leukocytes. Leukocyte counting
was performed using blood smears on glass slides. Blood samples
were also counted in a Neubauer chamber.
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FIGURE 1 | Flow cytometric analysis of dendritic cells (DCs) from BALB/c differentiated for 9 days in medium containing GM-CSF and IL-4. Cells were separated
according to granularity (SSC) and size (FSC) and double-labeling for CD11c and MHC-II was evaluated. In CD11c+/MHC-II+ populations (∼60%), expression of
CD80 and CD86 was also defined. Data were analyzed using FlowJo software (Tree Stars Inc.).
FIGURE 2 | Activation of DCs by peptide P10. DCs were analyzed for MHC-II, CD80 and CD86 expression (A) and frequency of CD80+/CD86+ cells (B). Analysis
by one-way ANOVA followed by Tukey’s post-test, where ∗p < 0.05, ∗∗p < 0.01 in comparison with unstimulated group (DC).
Intratracheal Infection
BALB/c mice were infected intratracheally (i.t.) with
P. brasiliensis Pb18 20 days after immunosuppression was
initiated. For the procedure, animals were anesthetized
intraperitoneally using ∼200 µl of a solution containing
80 mg/kg ketamine and 10 mg/kg xylazine (both from União
Química Farmacêutica, Brazil). Five minutes after the injection
of the anesthetics, a small longitudinal skin incision was made in
the neck to expose the trachea and 3 × 105 yeast cells in 50 µl of
PBS was injected. The incision was sutured with 5-0 silk.
Peptide Synthesis and Purification
P10 peptide with amidated C-terminal was purchased from
Peptide 2.0 (Chantilly, VA, United States). HPLC and MS
analyses performed by the manufacturer showed that the
synthetic P10 was 98% pure.
Dendritic Cells Differentiation
Dendritic cells were obtained from bone marrow as described
previously (Inaba et al., 1992). Briefly, femurs and tibias were
collected from male BALB/c mice and flushed with RPMI
(Vitrocell, Campinas, Brazil). Samples containing 107 cells were
cultivated in RPMI supplemented with 10% fetal calf serum (FCS;
Vitrocell), 20 µg/ml gentamicin (Gibco BRL Life Technologies,
Grand Island, NY, United States) and recombinant cytokines
GM-CSF (30 ng/ml) and IL-4 (15 ng/ml) (both from Peprotech,
Rocky Hill, NJ, United States) in 25 cm2 cell culture flasks. On
the second day, 80% of medium was removed and the same
amount of fresh medium with growth factors was added. On the
fourth, sixth, and eighth day, cell supernatants were centrifuged
and pellets were plated in fresh medium containing growth
factor. On the ninth day, cells were harvested and used in the
experiments.
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FIGURE 3 | Measurement of IL-10 and IL-12 cytokines in culture
supernatants of differentiated DCs ex vivo pulsed or not with P10 or IFN-γ.
Supernatants of DCs incubated in medium alone (DC; negative control) or
with either P10 (DC + P10) or IFN-γ (DC + IFN; positive control) were tested
for IL-10 and IL-12 production. Analysis by one-way ANOVA followed by
Tukey’s post-test, yielding ∗∗∗p < 0.001.
Expression of Costimulatory Molecules
and Kinetics of Cytokine Production on
DCs Pulsed with P10 or IFN-γ
Dendritic cells were distributed into 24-well plates at a 106/ml
cell density and cultivated in medium alone or with P10
(2.55 × 10−1 mM) at 5% CO2 and 37◦C. After 2 h, cells
were removed, washed in FACS buffer and incubated with
antibodies to CD11c (BV711, Clone N418), MHC-II (APC-Cy7,
Clone M5/114.15.2), CD86 (APC, Clone 16-10A1) and CD-80
(PE, GL1) for 30 min at 4◦C. Cells were analyzed by flow
cytometry (BD FACSCanto) to assess the expression of surface
molecules. In addition, culture supernatants of DCs pulsed with
or without P10 or IFN-γ (20 ng/ml) for 2, 12, and 24 h were
assessed for IL-10 and IL-12 production using enzyme-linked
immunosorbent assay (ELISA) kits (BD OpTeia, San Diego, CA,
United States).
In Vitro Activation of DCs and Treatment
of Infected Mice
Dendritic cells (106/ml) were distributed into 24-well plates
and cultivated in medium alone or with P10. After 2 h,
cells were harvested and a total of 3 × 105 cells were
injected subcutaneously in immunosuppressed mice 30 days
post-infection. Mice were also randomized to receive either
trimethoprim-sulfamethoxazole (TMP-SMX) 3–15 mg/kg every
day for 15 days. Controls groups were treated with PBS.
Fungal Burden in Organs of Infected
Mice
Mice were euthanized 45 days after infection (day 65 of
experiment) and lungs were removed. Portions of lung were
weighed, homogenized in PBS and aliquots were plated on
agar brain heart infusion (BHI) supplemented with 4% fetal
bovine serum (Gibco, Grand Island, NY, United States), 5%
supernatant of spent culture of P. brasiliensis Pb192, 10
FIGURE 4 | Total leukocyte counts in peripheral blood of BALB/c mice treated
with dexamethasone. Leukocyte counts of mice prior to the initiation of daily
dexamethasone administration (Day 0), on the day of infection (Day 20), after
randomization of mice into treatment groups (Day 50) and when mice were
euthanized (Day 65). The results shown are only from uninfected mice that did
not receive any DC preparations. Statistical analysis at day 20, 50, and 65
was done comparing the leukocyte levels to those measured before
dexamethasone treatments ∗∗∗p < 0.001. Analyses were by one-way ANOVA
followed by Tukey’s post-test.
IU/ml streptomycin-penicillin (Cultilab, Brazil) and 500 mg/ml
cycloheximide (Sigma, St. Louis, MO, United States) (Moscardi-
Bacchi et al., 1994). Plates were incubated at 37◦C for
20 days, and the resulting Colony Forming Units (CFUs) were
enumerated.
Cytokine Detection
Lung sections were homogenized in PBS with protease inhibitors:
benzamidine HCl (4 mM), EDTA disodium salt (1 mM),
N-ethylmaleimide (1 mM), and pepstatin (1.5 mM) (Sigma, St.
Louis, MO, United States). Supernatants were assayed for IL-4,
IL-10, IL-12, and IFN-γ using ELISA kits (BD OpTeia, San Diego,
CA, United States). The detection limits of the assays were as
follow: 7.8 pg/ml for IL-4, 31.3 pg/ml for IFN-γ and IL-10, and
62.5 pg/ml for IL-12, as determined by the manufacturer.
Histological Analyses
Additional lung sections were fixed in 10% buffered formalin and
embedded in paraffin for cutting. Sections were stained by the
Gomori-Grocott method and hematoxylin/eosin (HE).
Statistical Analysis
Data shown are representative of at least two independent
experiments. For in vivo experiments, a total of six animals per
group were used. In vitro experiments were done in triplicates
for each condition. Statistical analyses were performed using
GraphPad Prism 5 software (San Diego, CA, United States). The
results were expressed as mean values and standard deviations
(SD) of the indicated values. Tukey’s significant difference test
was employed for non-parametric data. p-values of ≤0.05 were
used to indicate statistical significance.
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FIGURE 5 | Total leukocyte counts in peripheral blood of BALB/c mice treated
with dexamethasone and infected with P. brasiliensis. Leukocyte counts were
obtained after mice were euthanized (Day 65). Except for Sham, all groups
were immunosuppressed with dexamethasone (DEX). Data show Sham
(uninfected without immunosuppression or any treatments), DEX-only
(uninfected and untreated), INFECT-only (infected and untreated), DC (infected
and treated with non-pulsed DCs), TMP-SMX (infected and treated with
sulfamethoxazole-trimethoprim), DC + TMP-SMX (infected and treated with
DCs and trimethoprim-sulfamethoxazole), DC + P10 (infected and treated with
P10-pulsed DCs) and DC + P10 + TMP-SMX (infected and treated with
P10-pulsed DCs with trimethoprim-sulfamethoxazole). Data shown are
representative of two independent experiments, analyzed by one-way ANOVA
followed by Tukey’s post-test, where ∗p < 0.05, ∗∗p < 0.01 or ∗∗∗p < 0.001
in comparison to DEX-only.
RESULTS
In Vitro Characterization of DCs
Dendritic cells from BALB/c mice were analyzed by flow
cytometry. Cell were first gated by granularity (SSC) and size
(FSC) and then analyzed for CD11c and MHC-II expression.
Double positive cells for CD11c and MHC-II were considered
as differentiated DCs, reaching a frequency of appropriately
60% (Figure 1), as previously observed (Magalhães et al., 2012).
Therefore, for in vivo experiments, each vaccine dose contained a
total of 3 × 105 cells, of which 1.8 × 105 were DCs pulsed or not
with P10.
Activation Dendritic Cells by Peptide P10
We assessed the expression of MHC-II, CD80, and CD86
molecules within MHCII+/CD11c+ cell population after 2 h
of stimulation with or without P10. According to the Median
Fluorescence Intensity (MFI), we observed a decrease in
MHC-II and increase of CD86 expression for P10-pulsed
DCs and no significant changes for CD80 in comparison
to control group (Figure 2A). However, the percentage of
CD80+/CD86+ DCs showed a significant increase (Figure 2B),
demonstrating that P10 might have a stimulatory effect for DCs
activation.
FIGURE 6 | Therapeutic delivery of P10-primed DCs significantly reduces
pulmonary fungal burden. Immunosuppressed mice (n = 6) were randomized
to different treatment groups 30 days after intratracheal infection with
P. brasiliensis. The treatment groups were INFECT-only (infected and
untreated), TMP-SMX (treated with sulfamethoxazole-trimethoprim); DC
(treated with non-pulsed dendritic cells); DC + TMP-SMX (treated with
non-pulsed DCs and TMP-SMX); DC + P10 (treated with P10-pulsed DCs);
DC + P10 + TMP-SMX (treated with P10-pulsed DCs and TMP-SMX treated).
Data shown are representative of two independent experiments, analyzed by
one-way ANOVA followed by Tukey’s post-test, where ∗∗p < 0.01 or
∗∗∗p < 0.001 in relation to INFECT-only and #p < 0.05 or ##p < 0.01 in
relation to DC.
Measurements of IL-10 and IL-12
Cytokines in Culture Supernatants of Ex
Vivo P10-Pulsed Dendritic Cells
Dendritic cells pulsed with P10 showed increased production of
IL-10 and IL-12 compared with untreated DCs (Figure 3). P10
induced an increased production of these cytokines, which was
even higher in DCs pulsed with IFN-γ, although these levels were
higher in the setting of IFN-γ at 12 and 24 h.
Immunosuppression of BALB/c Mice
with Dexamethasone
Dexamethasone administered in water “ad libitum” to mice over
a 65-day period significantly reduced the peripheral leukocyte
counts in a sustained manner (Figure 4). Figure 5 depicts
leukocyte counts on day 65, demonstrating decreased leukocyte
counts in all groups in comparison with non-immunosuppressed
mice (Sham). Leukocyte levels of immunosuppressed animals
(DEX-only) were statistically different from all groups treated
with DCs (DC, DC + TMP-SMX, DC-P10, DC + P10 + TMP-
SMX). All of the DC administration conditions increased
leukocyte levels in comparison to dexamethasone treated mice
(DEX only). However, treatment with DCs did not significantly
increase leukocyte levels in comparison to INFECT-only group.
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FIGURE 7 | Therapeutic administration of P10-primed DCs alters cytokine responses in the lungs of immunosuppressed mice infected with P. brasiliensis. IL-10,
TNF-α, IL-12, and IFN-γ cytokines were assayed in the lungs of mice 45 days after intratracheal infection. Immunosuppressed animals (n = 6) were randomized into
different groups: INFECT-only (infected and untreated), TMP-SMX (treated with sulfamethoxazole-trimethoprim); DC (treated with non-pulsed dendritic cells);
DC + TMP-SMX (treated with non-pulsed DCs and TMP-SMX); DC + P10 (treated with P10-pulsed DCs); DC + P10 + TMP-SMX (treated with P10-pulsed DCs and
TMP-SMX treated). Data shown are representative of two independent experiments, analyzed by one-way ANOVA followed by Tukey’s post-test, where ∗p < 0.05,
∗∗p < 0.01, or ∗∗∗p < 0.001 in comparison to INFECT-only.
Immunization with P10-Primed DCs
Reduces Fungal Burden
The pulmonary fungal burden of immunosuppressed mice
infected with P. brasiliensis was significantly reduced by
administration of either TMP-SMX or unprimed DCs (Figure 6).
The combination of unprimed DCs and TMP-SMX further
reduced CFUs. However, the greatest reduction occurred when
DCs primed with P10 were administered and this effect was
further augmented when TMP-SMX was added to therapy.
Pattern of Cytokines Induced by In Vivo
Treatment Using Dendritic Cells Pulsed
with P10
IL-10, IL-12, IFN-γ, and TNF-α levels were measured by ELISA
in the lungs of mice with different treatment regimens (Figure 7).
A significant reduction of IL-10 was observed in all groups that
received DCs with the greatest reduction occurring in mice that
received P10-primed DCs together with TMP-SMX. Increased
levels of IL-12 occurred in mice treated with P10-primed
DCs with or without TMP-SMX treatment. Levels of TNF-α
were reduced after the administration of DCs with TMP-SMX
or primed DCs, but were only significantly reduced in the
combination of primed DCs with TMP-SMX treatment. No
significant differences were detected in IFN-γ levels, although
there was a trend to lower levels in the groups treated with
TMP-SMX combined with either P10-primed or unprimed DCs.
Analysis of Histological Sections
Lung sections were subjected to Gomori-Grocott and HE
staining. Gomori-Grocott stained micrographics (Figure 8)
depict the fungal burden, showing the presence of fungal
cells in lung tissue. Figure 8A demonstrates uninfected
immunosuppressed mice with an absence of fungal
cells. Abundant fungal cells were present in tissues of
immunosuppressed mice in the following groups: infected and
not treated (Figure 8B), infected and treated with (Figure 8C)
and non-pulsed DCs treated groups (Figure 8D). In contrast,
lung sections from immunosuppressed and infected animals
treated with P10-pulsed DCs (Figure 8E), non-pulsed DCs and
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FIGURE 8 | Gomori-Grocott staining reveals that therapy with P10-primed DCs reduces pulmonary fungal load in P. brasiliensis infected mice. Representative
Gomori-Grocott stained lung sections from immunosuppressed mice 45 days after intratracheal infection with P. brasiliensis. (A) uninfected and untreated animals;
(B) infected and untreated; (C) infected and treated with TMP-SMX; (D) infected and treated with non-pulsed DCs; (E) infected and treated with P10-pulsed DCs;
(F) infected and treated with non-pulsed DCs in combination with TMP-SMX; (G) infected and treated with P10-pulsed DCs in combination with TMP-SMX.
Photographs were taken at 300× magnification. Bars denote 100 µm.
TMP-SMX (Figure 8F) and P10-pulsed DCs and TMP-SMX
(Figure 8G) had a significantly lower fungal burden. Moreover,
the animals that received P10-pulsed DCs (Figures 8E,G)
presented the lowest burden of fungal cells in lung tissue.
Hematoxylin/eosin staining (Figure 9) revealed normal
tissue architecture in non-infected mice (Figure 9A). It
was observed the presence of granulomas with fungal cells
and intense inflammatory infiltrates in lung parenchyma of
immunosuppressed and infected-only (Figure 9B), infected
and treated with TMP-SMX (Figure 9C) and infected and
treated with P10-pulsed DCs (Figure 9E) groups. Granuloma-
like structures were also observed in the other infected groups,
but inflammatory infiltrates were reduced in the non-pulsed
DCs (Figure 9D), non-pulsed DCs and TMP-SMX (Figure 9F)
and P10-pulsed DCs and TMP-SMX treated (Figure 9G)
groups. Lung parenchyma was significantly best preserved and
less compromised in P10-pulsed DCs and TMP-SMX treated
(Figure 9G) group.
DISCUSSION
Acute and sub-acute forms of PCM are highly aggressive in
the absence of early antifungal treatment immediately after the
disease manifestation and death remains a relatively common
outcome in this setting. Antifungal therapy requires a long and
exhausting approach to prevent relapses. In addition, standard
therapeutic regimens are associated with significant toxicities,
such as nephrotoxicity and hepatotoxicity, and intense therapy
does not prevent the development of disease sequelae, such as
pulmonary fibrosis or scarring (Shikanai-Yasuda et al., 2006;
Bocca et al., 2013; Buccheri et al., 2015). Hence, antifungal
therapy alone does not inhibit the intense inflammatory
responses in infected tissues that occur in response to the release
of fungal antigens from dead or dying cells resulting in extensive
tissue damage, which, in fact, can lead to death (Benard et al.,
2012). To combat this adverse host response, we have been
studying a therapeutic vaccine against P. brasiliensis based on
a peptide known as P10, which induces a strong, protective
immunological response that significantly reduces fungal burden,
tissue injury and fibrosis in a murine experimental PCM model
(Travassos et al., 2008a; Taborda et al., 2015).
Dendritic cells are potent stimulators of the immune response
and are able to activate naïve T cells by presenting peptide
antigens (Banchereau, 2000; Thind et al., 2015). Previously, we
have demonstrated that intravenous or subcutaneous injection
of P10-primed DCs into mice with established PCM led to
a significant reduction in fungal burden and stimulated a
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FIGURE 9 | Hematoxylin and Eosin staining reveals that therapy with P10-primed DCs reduces pulmonary damage in mice infected with P. brasiliensis.
Representative Hematoxylin/Eosin stained lung sections from immunosuppressed mice 45 days after intratracheal infection with P. brasiliensis. (A) uninfected and
untreated animals; (B) infected and untreated; (C) infected and treated with TMP-SMX; (D) infected and treated with non-pulsed DCs; (E) infected and treated with
P10-pulsed DCs; (F) infected and treated with non-pulsed DCs in combination with TMP-SMX; (G) infected and treated with P10-pulsed DCs in combination with
TMP-SMX. Photographs were taken at 300× magnification. Bars denote 100 µm.
Th1-biased cytokine response (Magalhães et al., 2012). Here we
demonstrated that in vitro DC stimulation with P10 increases
the frequency of CD80+/CD86+ DCs, while also increasing
the production of IL-12 by these cells. These data support
our hypothesis that P10 stimulation activates DCs resulting
in improved antigen presentation and T-cell responses that
culminate in protection against P. brasiliensis infection.
In the present study, we also evaluated the therapeutic
potential of P10-primed DCs in the setting of acute/subacute
PCM in immunocompromised mice using dexamethasone,
which effectively reduces airway inflammation through multiple
mechanisms (Muñoz et al., 2014). Dexamethasone administered
in drinking water for 20 days reduced the total number of
leukocytes by ∼40%. Infecting these mice with P. brasiliensis
Pb18 induced an aggressive disease that was similar to
the acute/subacute form of PCM. In fact, dexamethasone
immunosuppressed mice infected with 3 × 105 yeast cells
of Pb18 have 100% mortality within 80 days (Muñoz et al.,
2014). The administration of P10-primed DCs to dexamethasone
treated, Pb18 infected mice significantly reduced the fungal
burden, with the greatest reduction being achieved with
or without concomitant antifungal treatment. These results
were supported by the histological evaluations that revealed
the dramatic protection of the lung architecture along with
significant reductions in yeast cell numbers in mice treated with
primed DCs, especially in the setting of antifungal combination
therapy.
Protection against systemic fungal infection requires an
effective cell immune response and the presence of IL-12 and
IFN-γ appear to be essential to control the progression of
PCM (Travassos and Taborda, 2012a). We have previously
demonstrated that immunization with P10 can restore
lymphoproliferation in immunosuppressed animals (Muñoz
et al., 2014). In these prior experiments, murine DCs pulsed
in vitro with P10 or IFN-γ (used as a control) induced significant
IL-10, IL-12 production and enhanced MHC-II expression.
In general, DCs stimulated with IFN-γ induces mature cells
to preferentially produce IL-12, whereas DCs stimulated by
IL-10 and prostaglandin E2 generate low amounts of IL-12
(Banchereau, 2000). In our present study, lung homogenates
from immunosuppressed and Pb18 infected mice treated with
DCs pulsed with P10, with or without antifungal drugs, contained
significantly higher levels of IL-12 and significant reduction of
IL-10 levels compared with the lungs of immunosuppressed and
infected mice that did not receive DCs. The therapeutic use of
P10-primed DCs in our non-immunosuppressed murine PCM
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model also led to increased levels of IL-12 and reduced IL-10
levels in lung tissues, albeit high levels of IFN-γ were also
present at the time the mice were euthanized in the prophylactic
an therapeutic model (Magalhães et al., 2012). Similarly, we
have found significant increased levels of IFN-γ and IL-12 and
reduction of IL-10 level in the lungs of mice vaccinated with 20µg
of P10 in complete Freund’s adjuvant that were subsequently
infected with Pb18 (Muñoz et al., 2014). We believe that the peak
of IFN-γ expression is likely occurring at different times in these
different models, in which mice were also euthanized at different
time points after infection. This hypothesis is supported by the
present results, in which we found significant reductions of fungal
cells when P10-pulsed DCs were administered with or without
concomitant antifungal therapy.
CONCLUSION
Out data indicate that P10-pulsed DCs, in the presence or
not of antifungal drug, have the ability to induce specific
immunity against P. brasiliensis in animals previously treated
with corticosteroid in an experimental model that mimics the
most aggressive form of PCM. These findings further support the
active pursuit of P10 as a candidate for a human vaccine.
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